Recursion Pharmaceuticals (NASDAQ:RXRX) Posts Earnings Results, Misses Estimates By $0.01 EPS

Recursion Pharmaceuticals (NASDAQ:RXRX) released its earnings results on Wednesday. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01), Briefing.com reports. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the previous year, the business posted ($0.43) EPS. The firm’s quarterly revenue was up 147.6% on a year-over-year basis.

Recursion Pharmaceuticals Trading Down 0.6 %

RXRX stock opened at $6.93 on Friday. The business has a fifty day moving average price of $6.58 and a 200 day moving average price of $7.63. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. Recursion Pharmaceuticals has a fifty-two week low of $5.03 and a fifty-two week high of $15.74. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -4.28 and a beta of 0.81.

Insiders Place Their Bets

In related news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $7.12, for a total value of $81,502.64. Following the completion of the transaction, the director now directly owns 7,132,769 shares of the company’s stock, valued at $50,785,315.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $7.56, for a total value of $45,360.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,939,803.28. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $7.12, for a total value of $81,502.64. Following the transaction, the director now directly owns 7,132,769 shares in the company, valued at $50,785,315.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 171,682 shares of company stock valued at $1,107,868. 15.75% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on RXRX. Jefferies Financial Group decreased their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday. Finally, Leerink Partners dropped their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.